tbuckley/cabot-search huggingface dataset:
THU-180-Treatment of genotype 3 HCV infection in the large real-life “Navigatore Lombardia” multicentre cohort: Results from three different regimens
Authors: Alessandro Soria, Giuseppe Lapadula, Elisa Colella, Alessandra Gambaro, Anna Spolti, Nunzia Bottalico, Luisa Pasulo, Isabella Carderi, Sergio Lazzaroni, Roberto Boldizzoni, Luciana Scabeni, Paolo Del Poggio, Guido Colloredo Mels, Mariella Di Marco, Alberto Colombo, Valentina Grasso, Ombretta Spinelli, Marie Graciella Pigozzi, Massimo Graffeo, Angiola Spinetti, Canio Carriero, Barbara Menzaghi, Natalia Terreni, Paola Brambilla, Angelo Pan, Daniele Bella, Cecilia Liani, Silvia Polo, Gianpiero Aimo, Sherrie Bhoori, Paolo Bonfanti, Chiara Molteni, Federico Gatti, Paolo Viganò, Elena Dionigi, Riccardo Centenaro, Maria Vinci, Massimo Puoti, Marta Borghi, Roberta D’ambrosio, Elisabetta Degasperi, Roberta Soffredini, Luca Valenti, Roberto Gulminetti, Andrea Lombardi, Monica Schiavini, Simona Landonio, Giuliano Rizzardini, Andrea Capretti, Maria Grazia Rumi, Mauro Viganò, Alessia Giorgini, Esther Merlini, Anna De Bona, Antonella D’arminio Monforte, Caterina Uberti-Foppa, Hamid Hasson, Stefania Salpietro, Paolo Antonio Grossi, Alessio Aghemo, Sara Gritti, Franco Noventa, Pietro Lampertico, Stefano Fagiuoli
Journal: Journal of Hepatology (2019)
TCTAP A-132 Contrast Media Induced Hyperemia (Contrast FFR) Compared with Adenosine Induced Hyperemia in the Evaluation of Coronary Fractional Flow Reserve (FFR)
Authors: Tanyarat Aramsareewong, Seksak Moonsarn, Anuwat Rintarvitoon, Chanwat Pitinan, Thoranis Chantrarat
Journal: Journal of the American College of Cardiology (2019)
GS-15-Deficiency of the ABC transporter ABCC12/MRP9 is associated with chronic cholestasis syndromes and causes bile duct paucity in zebrafish and mouse model organisms
Authors: Lingfen Xu, Duc Hung Pham, Tiffany Shi, Jillian Ellis, Mary Mulen, Alexander Valencia, Sujit Mohanty, Sami Wali, Alexander Miethke, Chunyue Yin
Journal: Journal of Hepatology (2019)
THU-285-Loss of X-Box Protein-1 in intestinal epithelial cells promotes the development of alcoholic liver disease in the liver
Authors: kang Zheng, Hui Ye, Yulia Nevzorova, Beatriz Martin, Iris Asensio, Javier Vaquero, Manuel Gómez del Moral, Rafael Bañares, Eduardo Martínez-Naves, Francisco Javier Cubero
Journal: Journal of Hepatology (2019)
FRI-348-Monoacylglycerol lipase deletion protects against obesity-induced hepatic steatosis via PPARg regulation in adipose tissue and fatty acid malabsorption in the intestine
Authors: Matteo Tardelli, Francesca Bruschi, Thierry Claudel, Nicole Auer, Victoria Kunczer, Tatjana Stojakovic, Merima Herac, Sophie Lotersztajn, Michael Trauner
Journal: Journal of Hepatology (2019)
Fever, Rash, and Migratory Polyarthralgias
Authors: David C. Gaston, David R. Peaper, Sonali D. Advani
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SAT-211-HEV infection in Italy: Beyond the hepatic disease
Authors: Giovanna Picchi, Alessandra Ricciardi, Lara Marola, Elisabetta Madonna, Paola Chionne, Umbertina Villano, Cinzia Marcantonio, Roberto Bruni, Michele Equestre, Giulio Pisani, Nerio Iapadre, Maurizio Mariani, Antonio Cellini, Lucia Orneto, Remo Barnabei, Simonetta Santini, Margherita D’Alessandro, Pierluigi Cacciatore, Federica Sozio, Stefano Necozione, Giustino Parruti, Maurizio Paoloni, Annarita Ciccaglione, Alessandro Grimaldi
Journal: Journal of Hepatology (2019)
PS-120-Post progression survival in patients with intermediate-stage hepatocellular carcinoma after receiving transarterial chemoembolization
Authors: Yukiko Shima, Sadahisa Ogasawara, Yoshihiko Ooka, Kazufumi Kobayashi, Susumu Maruta, Hiroaki Kanzaki, Kengo Kanayama, Takahiro Maeda, Yuko Kusakabe, Soichiro Kiyono, Masato Nakamura, Tomoko Saito, Eiichiro Suzuki, Shingo Nakamoto, Shin Yasui, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Naoya Kato
Journal: Journal of Hepatology (2019)
Induction of Selenoprotein P mRNA during Hepatitis C Virus Infection Inhibits RIG-I-Mediated Antiviral Immunity
Authors: Kazuhisa Murai, Masao Honda, Takayoshi Shirasaki, Tetsuro Shimakami, Hitoshi Omura, Hirofumi Misu, Yuki Kita, Yumie Takeshita, Kiyo-aki Ishii, Toshinari Takamura, Takeshi Urabe, Ryogo Shimizu, Hikari Okada, Taro Yamashita, Yoshio Sakai, Shuichi Kaneko
Journal: Cell Host & Microbe (2019)
Correlation between EGFR mutations and expression of female hormone receptors in NSCLC: A meta-analysis.
Authors: Qihua He, Wenhua Liang, Jianrong Zhang, Jianxing He
Journal: Journal of Clinical Oncology (2015)

e22228 Background: Compared with males, female NSCLC patients represented more frequent EGFR mutations. Despite the difference in smoking history, an association between female hormones and EGFR mutation might be an underlying reason. Some evidence support this hypothesis, however, the existed results were inconclusive. We sought to examine the link between the expression of female hormone receptors and EGFR mutations in NSCLC. Methods: Electronic databases were searched for the relevant articles. The primary endpoints were the presence of EGFR mutations between different expression levels of estrogen receptor (ER) and progesterone receptor (PR). Results: After applying inclusion and exclusion criteria, five studies were included. The involved hormone receptors included ER (both α and β subtypes) and PR. Based on random-effects model, patients with high ER-β had significantly greater EGFR mutation rate than low ER-β patients (44.2% vs. 23.7%; OR 3.44, 95% CI 2.40 to 4.93, P < 0.001) without heterogeneity (Chi² = 0.62, P = 0.73, I² = 0%). There was no difference in EGFR mutations between high and low expression of ER-α (OR 1.18, 95% CI 0.62 to 2.33, P = 0.58; heterogeneity: P < 0.01, I² = 73%), as well as PR (OR 1.29, 95%CI 0.40 to 4.10, p = 0.67; heterogeneity: P = 0.08, I² = 68%). Conclusions: High ER-β expression is correlated with EGFR mutations in NSCLC, but not ER-α and PR. Although some trends were observed, the correlation between female hormone receptors and EGFR mutations was still not valid. Next, we are going to clarify this issue based on a large database from our center.
Clinical Credence — SGLT2 Inhibitors, Diabetes, and Chronic Kidney Disease
Authors: Julie R. Ingelfinger, Clifford J. Rosen
Journal: New England Journal of Medicine (2019)

The number of people who die from kidney disease every year has risen over the past decade and is now estimated at 5 million to 10 million worldwide. The increase in rates of obesity — along with associated rates of type 2 diabetes, hypertension, and cardiovascular disease — has principally driven the elevated mortality. More than 660,000 Americans have reached the point of requiring intervention for end-stage kidney disease, with 468,000 receiving dialysis and more than 193,000 undergoing kidney transplantation, leading to a major public health and economic burden.1 Hence, the development of new treatments that may prevent or delay . . .
Subgroup analyses by performance status (PS) in the phase III SQUIRE study: First-line necitumumab (N) plus gemcitabine-cisplatin (GC) vs. GC in squamous non-small cell lung cancer (NSCLC).
Authors: Mark A. Socinski, Alexander Luft, Aleksandra Szczesna, Wojciech Szafranski, Rinat Galiulin, Beatrix Bálint, Keunchil Park, Martin Reck, Henrik Depenbrock, Shivani Nanda, Nadia Chouaki, Nick Thatcher
Journal: Journal of Clinical Oncology (2015)

e19023 Background: As previously reported, the SQUIRE study demonstrated that the addition of N to GC chemotherapy significantly improved survival in patients (pts) with stage IV squamous NSCLC. Here we present overall survival (OS), progression-free survival (PFS), and safety results for Eastern Cooperative Oncology Group (ECOG) PS subgroups. Methods: In this multicenter, open-label study, pts with stage IV squamous NSCLC were randomized 1:1 to N (800 mg iv, days 1 and 8) plus GC (G = 1250 mg/m² iv, days 1 and 8; C = 75 mg/m² iv, day 1) or GC alone every 21 days for up to six cycles. N+GC pts without progression continued on N alone until progressive disease or intolerable toxicity. Preplanned subgroup analyses were performed for ECOG PS 0–1 and 2. Results: Subgroups PS 0–1/2 (n = 996 [91%]/n = 96 [9%]) were well balanced regarding baseline characteristics (males, 83%/86%; median age, 62/65 yrs). For the overall median relative dose intensity, GC was similar between arms for PS subgroups, whereas N (overall) was higher for the PS 0–1 than for PS 2 subgroup (94.8% and 90.0%). Post-study therapy use was generally higher in the PS 0–1 than in the PS 2 subgroup, but was balanced between the two arms. The OS hazard ratio (HR) for N+GC vs. GC was 0.85 (95% CI: 0.74, 0.98; p = 0.026) for PS 0–1 and 0.78 (95% CI: 0.51, 1.21; p = 0.275) for PS 2. The PFS HR (N+GC vs. GC) was 0.86 (95% CI: 0.75, 0.99; p = 0.035) for PS 0–1 and 0.79 (95% CI: 0.50, 1.24; p = 0.292) for PS 2. Select treatment-emergent adverse events (TEAEs) are shown in the table. Conclusions: A consistent treatment effect in favor of N+GC for OS and PFS was seen across subgroups including ECOG PS 2 pts. Administration of N+GC was well-tolerated in PS 2 pts, with no evidence of an increased safety risk in this subgroup. Clinical trial information: NCT00981058.Select TEAEs. Grade ≥ 3 Event PS 0-1* N+GC (%) PS 0-1* GC (%) PS 2† N+GC (%) PS 2† GC (%) Neutropenia‡ 25.5 28.1 12.5 21.7 Febrile neutropenia 0.6 1.4 2.1 0 Hypomagnesemia‡ 9.8 1.0 4.2 2.2 Rash‡ 7.8 0.4 0 0 Arterial thromboembolic events‡ 3.7 1.8 6.3 4.3 Venous thromboembolic events‡ 5.5 2.6 0 2.2 *n=985. †n=94. ‡Consolidated adverse event terms.
Abstract 18014: Carotid Lumen Diameter Improves Mortality Risk Prediction Compared to Intima Media Thickness in the Population-Based Study of Health in Pomerania
Authors: Felix Fritze, Stefan Groß, Till Ittermann, Lukas Petersen, Henry Völzke, Stephan Felix, Ulf Schminke, Marcus Dörr, Martin Bahls
Journal: Circulation (2017)

Introduction: Common carotid intima media thickness (IMT) is commonly used for cardiovascular (CV) risk prediction in clinical practice. During the atherogenic process IMT is thought to continuousl...
TCTAP C-010 Revascularization in Anteroseptal ST-segment Elevation Myocardial Infarction with Chronic Total Occlusion in Left Coronary Artery and Cardiogenic Shock
Authors: Andreas Erick Haurissa, Johan Gunadi, Deddy Hermawan Susanto, Grace Pingkan Ingrid Lumentut, Agustinus Mahardhika Sarayar, Janry Antonius Pangemanan, Agnes Lucia Panda
Journal: Journal of the American College of Cardiology (2019)
Abstract 10883: C-GRApH: A Validated Scoring System for the Early Risk Stratification of Neurologic Outcomes After Out-of-hospital Cardiac Arrest Treated With Therapeutic Hypothermia
Authors: Erich L Kiehl, Alex M Parker, Ralph M Matar, Matthew Gottbrecht, Michelle C Johansen, Mark P Adams, Lori A Griffiths, Katherine L Bidwell, Venugopal Menon, Kyle B Enfield, Lawrence W Gimple
Journal: Circulation (2015)

Background: Out of hospital cardiac arrest (OHCA) has 90% mortality, primarily from neurologic injury. Due to a lack of accurate early risk stratification models, guidelines advocate delayed prognostication of neurologic outcomes (NO) ≥72 hours post OHCA in patients treated with therapeutic hypothermia (TH). Here, we derive and validate a scoring system that uses objective data available at hospital presentation to risk stratify NO early post OHCA in the TH era. Methods: Demographics, pre OHCA diagnoses, arrest characteristics, and initial lab studies were compared between favorable and poor NO at hospital discharge, defined as cerebral performance category (CPC) 1-2 and 3-5 respectively, in a derivation cohort of 122 consecutive adult patients treated with TH (32-34 o C) post OHCA at a tertiary care US hospital from 2008-12. Inputs meeting a priori cutoffs ρ&lt;0.1 in univariate and ρ&lt;0.05 in subsequent stepwise multivariable analyses were dichotomized to create a scoring system (C-GRApH) with equal weighting. C-GRApH was validated internally from 2013-4 (n=72) and externally at a larger health system (quaternary care and satellite hospitals) from 2012-4 (n=272). Results: In the derivation and validation cohorts, 34 and 32% of patients survived to discharge, 27 and 21% with favorable NO respectively. The C-GRApH score (range 0-5) includes the following variables: pre-OHCA CAD (C); initial glucose &gt;200 (G); non VT/VF rhythm of arrest (R); age &gt;45 (A); and initial pH ≤7.0 (pH). The c-statistic was 0.82 for predicting poor NO in both cohorts with similar risk stratification observed. Favorable NO at hospital discharge was 70% in low (≤1, n=60), 20% in medium (2-3, n=307), and 2% in high (≥4, n=97) scores in the composite cohort. Conclusions: The C-GRApH score effectively stratifies NO in OHCA treated with TH early post-arrest using data readily available at initial presentation and identifies a subset of patients (scores≥4) where TH and intensive care are of limited benefit.
Molecular grouping and outcomes of young children with newly diagnosed ependymoma treated on the multi-institutional SJYC07 trial
Authors: Santhosh A Upadhyaya, Giles W Robinson, Arzu Onar-Thomas, Brent A Orr, Catherine A Billups, Daniel C Bowers, Anne E Bendel, Tim Hassall, John R Crawford, Sonia Partap, Paul G Fisher, Ruth G Tatevossian, Tiffany Seah, Ibrahim A Qaddoumi, Anna Vinitsky, Gregory T Armstrong, Noah D Sabin, Christopher L Tinkle, Paul Klimo, Danny J Indelicato, Frederick A Boop, Thomas E Merchant, David W Ellison, Amar Gajjar
Journal: Neuro-Oncology (2019)

Abstract Background This report documents the clinical characteristics, molecular grouping, and outcome of young children with ependymoma treated prospectively on a clinical trial. Methods Fifty-four children (aged ≤3 y) with newly diagnosed ependymoma were treated on the St Jude Young Children 07 (SJYC07) trial with maximal safe surgical resection, 4 cycles of systemic chemotherapy, consolidation therapy using focal conformal radiation therapy (RT) (5-mm clinical target volume), and 6 months of oral maintenance chemotherapy. Molecular groups were determined by tumor DNA methylation using Infinium Methylation EPIC BeadChip and profiled on the German Cancer Research Center/Molecular Neuropathology 2.0 classifier. Results One of the 54 study patients had metastases (cerebrospinal fluid positive) at diagnosis. Gross or near-total resection was achieved in 48 (89%) patients prior to RT. At a median follow-up of 4.4 years (range, 0.2–10.3 y), 4-year progression-free survival (PFS) was 75.1% ± 7.2%, and overall survival was 92.6% ± 4.4%. The molecular groups showed no significant difference in PFS (4-year estimates: posterior fossa ependymoma group A [PF-EPN-A; 42/54], 71.2% ± 8.3%; supratentorial ependymoma positive for v-rel avian reticuloendotheliosis viral oncogene homolog A [ST-EPN-RELA; 8/54], 83.3% ± 17.0%; and supratentorial ependymoma positive for Yes-associated protein [4/54], 100%, P = 0.22). Subtotal resection prior to RT was associated with an inferior PFS compared with gross or near-total resection (4-year PFS: 41.7% ± 22.5% vs 79.0% ± 7.1%, P = 0.024), as was PF-EPN-A group with 1q gain (P = 0.05). Histopathologic grading was not associated with outcomes (classic vs anaplastic; P = 0.89). Conclusions In this prospectively treated cohort of young children with ependymoma, ST-EPN-RELA tumors had a more favorable outcome than reported from retrospective data. Histologic grade did not impact outcome. PF-EPN-A with 1q gain and subtotal resection were associated with inferior outcomes.
New York City mayor declares measles public health emergency
Authors: Janice Hopkins Tanne
Journal: BMJ (2019)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following New York City mayor declares measles public health emergency Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
SAT-255-Long-term safety and efficacy results in hepatitis C virus genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in the TOPAZ-I and TOPAZ-II trials
Authors: Fred Poordad, Rui Sarmento E. Castro, Armen Asatryan, Humberto Aguilar, Patrice Cacoub, Douglas Dieterich, Rui Marinho, Armando Carvalho, Asma Siddique, Yiran Hu, Mariem Charafeddine, Mark Bondin, Nader Khan, Daniel Cohen, Franco Felizarta
Journal: Journal of Hepatology (2019)
GRP78-targeted ferritin nanocaged ultra-high dose of doxorubicin for hepatocellular carcinoma therapy
Authors: Bing Jiang, Ruofei Zhang, Jianlin Zhang, Yaxin Hou, Xuehui Chen, Meng Zhou, Xiuyun Tian, Chunyi Hao, Kelong Fan, Xiyun Yan
Journal: Theranostics (2019)

Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer deaths, primarily due to its high incidence of recurrence and metastasis.Considerable efforts have therefore been undertaken to develop effective therapies; however, effective anti-HCC therapies rely on identification of suitable biomarkers, few of which are currently available for drug targeting.Methods: GRP78 was identified as the membrane receptor of HCC-targeted peptide SP94 by immunoprecipitation and mass spectrum analysis.To develop an effective anti-HCC drug nanocarrier, we first displayed GRP78-targeted peptide SP94 onto the exterior surface of Pyrococcus furiosus ferritin Fn (HccFn) by genetic engineering approach, and then loaded doxorubicin (Dox) into the cavities of HccFn via urea-based disassembly/reassembly method, thereby constructing a drug nanocarrier called HccFn-Dox.Results: We demonstrated that HccFn nanocage encapsulated ultra-high dose of Dox (up to 400 molecules Dox/protein nanocage).In vivo animal experiments showed that Dox encapsulated in HccFn-Dox was selectively delivered into HCC tumor cells, and effectively killed subcutaneous and lung metastatic HCC tumors.In addition, HccFn-Dox significantly reduced drug exposure to healthy organs and improved the maximum tolerated dose by six-fold compared with free Dox. Conclusion:In conclusion, our findings clearly demonstrate that GRP78 is an effective biomarker for HCC therapy, and GRP78-targeted HccFn nanocage is effective in delivering anti-HCC drug without damage to healthy tissue.
FOXP3Δ3, the major isoform of FOXP3, promotes proliferation, migration, and invasion in non-small cell lung cancer
Authors: H. Jia, H. Qi, J. Peng, M. Li, G.G. Chen
Journal: Annals of Oncology (2019)

Background: Increasing evidence has shown that FOXP3 is not only expressed in immune cells but also in tumor cells. However, the results of tumor FOXP3 is inconsistent and even the opposite. Unlike mice, humans express multiple isoforms of FOXP3. However, the expression and role of FOXP3 isoforms in cancers are still largely unknown. The role of FOXP3 and FOXP3Δ3 in NSCLC remains unclear. Methods: The expression of FOXP3 and four FOXP3 isoforms was analyzed using the RSEM method for 32 cancer types from TCGA databases. The correlation between the expression of FOXP3 and prognosis of NSCLC patients was analyzed (http://kmplot.com/). Western blots assay, colony formation assay, MTT assay, wound-healing assay, and cell invasion assay were performed to determine the cell functions and to measure the expression of related molecules after the ectopic expression of FOXP3 and FOXP3Δ2 in NSCLC cells. Results: The expression of FOXP3 was upregulated in NSCLC tissues compared to adjacent non-tumor lung tissues. The FOXP3Δ3 was the most frequent FOXP3 isoform detected in NSCLC as well as in almost all types of cancers. The high expression of FOXP3 was correlated with poor prognosis in NSCLC. Tumor cells with FOXP3Δ3 were much more oncogenic than those without, and the ectopic expression of either FOXP3FL or FOXP3Δ3 could promote the proliferation, migration, and invasion of A549 and H23 cells. The ectopic expression of FOXP3 and FOXP3Δ3 downregulated E-cadherin and upregulated N-cadherin, snail, slug, MMP2, and MMP7. Conclusions: FOXP3Δ3 is the major isoform of FOXP3 in NSCLC and it may be a predictive factor for NSCLC patients. Legal entity responsible for the study: The Chinese University of Hong Kong. Funding: Research Grants Council of the Hong Kong SAR (No: CUHK462613) and the National Natural Science Foundation of China (No: 81472742). Disclosure: All authors have declared no conflicts of interest.
Congenital Absence of the Pulmonary Valve
Authors: ROBERT A. MILLER, MAURICE LEV, MILTON H. PAUL
Journal: Circulation (1962)

A group of cases of tetralogy of Fallot with congenital absence of the pulmonary valve are presented, and it is indicated that this abnormality presents a characteristic clinical, physiologic, and pathologic syndrome. It is postulated that the aneurysmal dilatation of the pulmonary artery may result either from a congenital weakness at the base of the pulmonary artery or from the hemodynamic effects of a ventricular septal defect and infundibular stenosis in the presence of pulmonary regurgitation. The absence of the pulmonary valve has not been a deterrent to successful corrective surgery aimed at the basic pathology of tetralogy of Fallot in three cases.
PS-026-FOXOl-activitiy controls effector function of CXCR6+CD8+ T-cells and prevents liver immune pathology during viral hepatitis and non-alcoholic steatohepatitis
Authors: Michael Dudek, Dominik Pfister, Nina Kallin, Dirk Wohlleber, donakonda sainitin, Mathias Heikenwalder, Percy A. Knolle
Journal: Journal of Hepatology (2019)
Video Telehealth Pulmonary Rehabilitation Intervention in Chronic Obstructive Pulmonary Disease Reduces 30-Day Readmissions
Authors: Surya P. Bhatt, Siddharth B. Patel, Erica M. Anderson, Daniel Baugh, Tina Givens, Christopher Schumann, J. Gregory Sanders, Samuel T. Windham, Gary R. Cutter, Mark T. Dransfield
Journal: American Journal of Respiratory and Critical Care Medicine (2019)